Spruce Biosciences, Inc. (SPRB) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SPRB Revenue Growth
SPRB Revenue Analysis (2018–2025)
As of May 8, 2026, Spruce Biosciences, Inc. (SPRB) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, SPRB's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.1 million in 2023.
When compared to Healthcare sector peers including CORT (+12.2% YoY), XNCR (-32.5% YoY), and NTLA (+16.9% YoY), SPRB has underperformed the peer group in terms of revenue growth. Compare SPRB vs CORT →
SPRB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SPRBCurrent | $0 | -100.0% | - | - | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 XNCR | $126M | -32.5% | +0.5% | -141.4% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACRS | $8M | -58.2% | +3.8% | -975.9% |
SPRB Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-21,000 | - | $-36,513,000 | - |
| 2024 | $4.9M | -51.3% | $4.9M | 100.0% | $-56,151,000 | -1143.4% |
| 2023 | $10.1M | - | $10.1M | 100.0% | $-51,993,000 | -515.3% |
| 2022 | $0 | - | $0 | - | $-47,283,000 | - |
| 2021 | $0 | - | $0 | - | $-42,066,000 | - |
| 2020 | $0 | - | $0 | - | $-29,416,000 | - |
| 2019 | $0 | - | $-12,000 | - | $-13,107,000 | - |
| 2018 | $0 | - | $-1,000 | - | $-9,972,000 | - |
See SPRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SPRB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSPRB — Frequently Asked Questions
Quick answers to the most common questions about buying SPRB stock.
Is SPRB's revenue growth accelerating or slowing?
SPRB revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is SPRB's long-term revenue growth rate?
Spruce Biosciences, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is SPRB's revenue distributed by segment?
SPRB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.